Sugi Predict

Sugi Predict / Compounds / SCHEMBL3424648

SCHEMBL3424648

SCHEMBL3424648

CCCCCCCCCCCCCCCCC1(C)CCc2c(C)c(OCCO)c(C)c(C)c2O1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PSEN1 P49768 8/20 0.59
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ PDE4A P27815 1/20 0.47
▸ PDE3A Q14432 1/20 0.47
▸ GSTO1 P78417 2/20 0.46
▸ NR1I2 O75469 2/20 0.46
▸ MAPT P10636 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ GSTP1 P09211 1/20 0.44
▸ TTPA P49638 1/20 0.44
▸ USP2 O75604 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ CYP4F2 P78329 1/20 0.44
▸ PTPN1 P18031 1/20 0.43
▸ ALOX5 P09917 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20024670 0.93 PSEN1 (0.63) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL12064998 0.92 PSEN1 (0.66) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL13084640 0.88 PSEN1 (0.55) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL627615 0.87 PSEN1 (0.64) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL13084723 0.86 PSEN1 (0.52) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL628447 0.86 PSEN1 (0.57) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL628411 0.86 PSEN1 (0.57) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL627937 0.86 PSEN1 (0.66) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL12064790 0.85 PSEN1 (0.67) PSEN1MEN1KMT2APDE4APDE3A
SCHEMBL13084628 0.85 PSEN1 (0.67) PSEN1MEN1KMT2APDE4APDE3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220403377-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. 2022-12-22 — — US disclosed
US-11312957-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2022-04-26 — — US disclosed
US-10676740-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2020-06-09 — — US disclosed
US-20190345498-A1 MODIFIED iRNA AGENTS BANK OF AMERICA, N.A. 2019-11-14 — — US disclosed
US-20180258427-A1 MODIFIED iRNA AGENTS BANK OF AMERICA, N.A. 2018-09-13 — — US disclosed
US-20160264968-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. 2016-09-15 — — US disclosed
US-20160264968-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. 2016-09-15 — — US disclosed
US-9394540-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-07-19 — — US disclosed
US-9394540-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-07-19 — — US disclosed
US-20140316124-A1 MODIDIFED iRNA AGENTS BANK OF AMERICA, N.A. 2014-10-23 — — US disclosed
US-8796436-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2014-08-05 — — US disclosed
US-20130211063-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-15 — — US disclosed
US-20130211063-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-15 — — US disclosed
US-8507661-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
US-8507661-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
US-20100292455-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS (US) 2010-11-18 — — US disclosed
US-20100292455-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS (US) 2010-11-18 — — US disclosed
US-7745608-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2010-06-29 — — US disclosed
US-7745608-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2010-06-29 — — US disclosed
US-20050107325-A1 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs ALNYLAM PHARMACEUTICALS, INC. 2005-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220403377-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 PSEN1 4510/4885MEN1 630/4885KMT2A 1975/4885
US-20190345498-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 PSEN1 4510/4885MEN1 630/4885KMT2A 1975/4885
US-20100292455-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 PSEN1 4510/4885MEN1 630/4885KMT2A 1975/4885
US-20180258427-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 PSEN1 4510/4885MEN1 630/4885KMT2A 1975/4885
US-10676740-B2 Modified iRNA agents NCL, HNRNPA0, HNRNPA1 PSEN1 4510/4885MEN1 630/4885KMT2A 1975/4885
US-20050107325-A1 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs LDLR, SLC29A1, SLC29A2 PSEN1 3773/4885MEN1 1466/4885KMT2A 3071/4885
US-11312957-B2 Modified iRNA agents NCL, HNRNPA0, HNRNPA1 PSEN1 4510/4885MEN1 630/4885KMT2A 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.